Avalo Therapeutics, Inc. (AVTX)
| Market Cap | 801.77M +379.5% |
| Revenue (ttm) | 59,000 -86.6% |
| Net Income | -100.33M |
| EPS | -4.18 |
| Shares Out | 53.63M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 932,348 |
| Open | 15.24 |
| Previous Close | 15.33 |
| Day's Range | 14.78 - 15.57 |
| 52-Week Range | 12.41 - 24.27 |
| Beta | 0.69 |
| Analysts | Strong Buy |
| Price Target | 44.08 (+194.85%) |
| Est. Earnings | Nov 5, 2026 |
About AVTX
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1β-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1β, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Financial Performance
In 2025, Avalo Therapeutics's revenue was $59,000, a decrease of -86.62% compared to the previous year's $441,000. Losses were -$78.26 million, 122.8% more than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for AVTX stock is "Strong Buy." The 12-month stock price target is $44.08, which is an increase of 194.85% from the latest price.
News
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
WAYNE, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immu...
Avalo Therapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
Abdakibart demonstrated strong efficacy and safety in phase II for HS, supporting advancement to phase III in 2027. The company is expanding its IL-1 beta franchise with AVTX-010 and maintains a robust cash position to fund development through 2029.
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immu...
Avalo Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Innovative therapies for inflammatory diseases are advancing, with abdakibart showing strong phase II efficacy and safety in HS, and a next-generation antibody in development. The company is well-capitalized and poised for key milestones, including phase III initiation and pipeline expansion.
Avalo Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A clinical-stage biotech is advancing its potent anti-IL-1 beta antibody, abdakibart, into phase III for HS after strong phase II results and positive physician feedback. Expansion plans include a long-acting version and new indications in dermatology and rheumatology, with robust financial backing and a focus on differentiated dosing and device strategy.
Avalo Therapeutics to Participate in Upcoming Investor Conferences
WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immu...
Avalo Therapeutics price target lowered to $48 from $50 at Guggenheim
Guggenheim lowered the firm’s price target on Avalo Therapeutics (AVTX) to $48 from $50 and keeps a Buy rating on the shares.
Avalo Therapeutics price target lowered to $30 from $35 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Avalo Therapeutics (AVTX) to $30 from $35 and keeps a Buy rating on the shares. The firm says the Phase 3 design…
Avalo Therapeutics reports Q2 EPS (83c), consensus (62c)
“In the second quarter, we achieved the key objectives that positioned Avalo for its next phase of growth,” said Garry Neil, Chief Executive Officer of Avalo. “We delivered positive topline…
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immun...
Avalo Therapeutics Quarterly report: Q2 2026
Avalo Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Avalo Therapeutics Earnings release: Q2 2026
Avalo Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Avalo Therapeutics Slides: Corporate presentation
Avalo Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
WAYNE, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for...
Avalo Therapeutics files to sell 128,189 shares of common stock for holders
16:04 EDT Avalo Therapeutics (AVTX) files to sell 128,189 shares of common stock for holders
Avalo Therapeutics Registration statement: Registration filing
Avalo Therapeutics filed a registration statement on July 17, 2026, providing details about a securities offering with the SEC.
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
WAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for...
Avalo Therapeutics initiated with an Outperform at Leerink
Leerink initiated coverage of Avalo Therapeutics (AVTX) with an Outperform rating and $38 price target With de-risked Phase 2 data in hand for abdakibart, the firm believes Avalo Therapeutics offers…
Avalo Therapeutics to join Russell 2000, Russell 3000
Avalo Therapeutics (AVTX) announced that it will be added to the small-cap Russell 2000 Index and the broad-market Russell 3000 Index, effective after the close of U.S. equity markets on…
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
WAYNE, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for...
Avalo Therapeutics Appoints Ron Philip to Board of Directors
WAYNE, Pa., June 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for...
Avalo Therapeutics advances AVTX-010
Avalo Therapeutics (AVTX) announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1beta monoclonal antibody with the potential for development in hidradenitis suppurativa as well ...
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
WAYNE, Pa., June 16, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated i...
Avalo Therapeutics Slides: Corporate presentation
Avalo Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
Avalo Therapeutics initiated with a Buy at BofA
BofA initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and $35 price target The firm sees Avalo as a “cleaner, single-asset immunology story” after the positive Phase 2…